CompletedNCT01959659
What is this study about?This completed observational study examined healthcare use and the impact of persistent schizophrenia symptoms despite adequately dosed antipsychotic treatment.
This study has finished and is no longer accepting participants.
Multiple locations, including EppingSchizophreniaObservational studyAges 18+
- Countries
- Australia, France, Czechia, + 4 others
- Sponsor
- Hoffmann-La Roche
CompletedNCT01606254
Official study titleA Repeated Dose Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In IchikawaSchizophreniaMedication studyAges 20–65
- Countries
- Japan
- Sponsor
- Janssen Pharmaceutical K.K.
CompletedNCT01812642
What is this study about?This study evaluated the safety of JNJ-37822681 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including AntwerpSchizophreniaMedication studyAges 20–55
- Countries
- Belgium, Germany, Russia, + 2 others
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT02804568
What is this study about?This study evaluated the safety of ALKS 3831 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Alkermes, Inc.
CompletedNCT02477020
What is this study about?Researchers compared TAK-063 20 mg and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including SpringdaleSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Takeda
CompletedNCT01678755
What is this study about?Researchers compared ABT-126 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including ChinoSchizophreniaMedication studyAges 20–55
- Countries
- United States
- Sponsor
- AbbVie (prior sponsor, Abbott)
CompletedNCT02873208
What is this study about?Researchers studied ALKS 3831, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Alkermes, Inc.
CompletedNCT00915512
Official study titleAn Open-label, Single-arm, Multicenter, Phase IV Study to Evaluate the Response to Treatment and Safety of Flexible Dose Treatment With Extended-release Paliperidone in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including AdanaSchizophreniaMedication studyAges 18–65
- Countries
- Türkiye
- Sponsor
- Janssen-Cilag Turkey
CompletedNCT01015001
Official study titleA Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With Clozapine
This study has finished and is no longer accepting participants.
In Porto AlegreSchizophreniaPlacebo comparisonAges 18–65
- Countries
- Brazil
- Sponsor
- Hospital de Clinicas de Porto Alegre
CompletedNCT07671040
Official study titleEffects of Adjunctive Structured Supportive Psychotherapy on Cognitive Function and Serum High-Sensitivity C-Reactive Protein in Schizophrenia: A Pilot Randomized Controlled Trial
This study has finished and is no longer accepting participants.
In MakassarSchizophreniaMedication studyAges 20–45
- Countries
- Indonesia
- Sponsor
- Hasanuddin University
CompletedNCT01232790
Official study titleA Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia
This study has finished and is no longer accepting participants.
In New HavenSchizophreniaPlacebo comparisonAges 18–60
- Countries
- United States
- Sponsor
- Yale University
CompletedNCT02476877
Official study titleA Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse
This study has finished and is no longer accepting participants.
In BrooklynSchizophrenia, Bipolarity, ...Observational studyAges 18+
- Countries
- United States
- Sponsor
- Advanced Clinical Laboratory Solutions, Inc.